Nektar Therapeutics
Pembelian
Diupdate

NKTR Risky LONG Trade

Although this seems to be a risky long trade. The reward is looking promising. Looking at the fundamentals, this company is well positioned with Cash. Debt is manageable even though the company is burning through cash (but that what most healthcare companies do until their products get FDA approval). Targets and Stops are in the graphic.
Trade aktif
Trade aktif
Trade aktif

Pernyataan Penyangkalan